Company Profile
Aligos Therapeutics Stock Price, News & Analysis
- Ticker:
- ALGS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.51 USD (+16.24%)
Close
Last updated: August 6, 2026
32.5M USD
Market cap
Why the stock is moving
Following the latest company update, “Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results”, ALGS closed up 16.2% at $5.51 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Liver and Viral Diseases
Aligos Therapeutics develops small-molecule and oligonucleotide therapies for liver and viral diseases. Its lead clinical effort targets chronic hepatitis B through suppression of viral antigen production.
Pevifoscorvir Sodium
Pevifoscorvir sodium is an antisense oligonucleotide designed to reduce hepatitis B surface antigen. The candidate is being evaluated in the Phase 2 B-SUPREME study across HBeAg-positive and HBeAg-negative patient cohorts.
Combination-Oriented Development
Aligos is assessing whether deep antigen reduction can improve immune control and support finite treatment strategies, potentially in combination with other antiviral or immunomodulatory agents.
Future catalysts
Second interim analysis from the HBeAg-positive B-SUPREME cohort in the second half of 2026.
Topline data from both HBeAg-positive and HBeAg-negative B-SUPREME cohorts in 2027.
Recent news
- 01
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
Source: Aligos Therapeutics
- 02
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
Source: Aligos Therapeutics
- 03
- 04
- 05
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
Source: Aligos Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aligos Therapeutics (ALGS)?
Aligos Therapeutics (ALGS) most recently closed at 5.51 USD, a +16.24% move versus the previous session.
What is the market cap of Aligos Therapeutics (ALGS)?
Aligos Therapeutics currently has a market capitalization of 32.5M USD on BioPharmSignal.
What does Aligos Therapeutics do?
Liver and Viral Diseases Aligos Therapeutics develops small-molecule and oligonucleotide therapies for liver and viral diseases. Its lead clinical effort targets chronic hepatitis B through suppression of viral antigen production. Pevifoscorvir Sodium Pevifoscorvir sodium is an antisense oligonucleotide designed to reduce hepatitis B surface antigen. The...
On which exchange is ALGS stock listed?
Aligos Therapeutics (ALGS) is associated with NASDAQ, United States, Biopharma.
What is Liver?
Liver and Viral Diseases Aligos Therapeutics develops small-molecule and oligonucleotide therapies for liver and viral diseases.
Which conditions is Aligos Therapeutics targeting with Liver?
Liver and Viral Diseases Aligos Therapeutics develops small-molecule and oligonucleotide therapies for liver and viral diseases. Its lead clinical effort targets chronic hepatitis B through suppression of viral antigen production. Pevifoscorvir Sodium Pevifoscorvir sodium is an antisense oligonucleotide designed to reduce hepatitis B surface antigen. The...
How does Aligos Therapeutics describe recent progress with Liver?
Second interim analysis from the HBeAg-positive B-SUPREME cohort in the second half of 2026. Topline data from both HBeAg-positive and HBeAg-negative B-SUPREME cohorts in 2027.
What is Viral?
Liver and Viral Diseases Aligos Therapeutics develops small-molecule and oligonucleotide therapies for liver and viral diseases.